Related Experiment Video
Updated: Mar 2, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease
Christiane Engelbertz1, Holger Reinecke1
1Department fur Kardiologie und Angiologie, Universitatsklinikum Munster, Münster.
Insights
Chronic kidney disease (CKD) patients with atrial fibrillation (AF) face high risks of stroke and bleeding. This review examines current data on anticoagulation treatments for these high-risk patients.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is a growing global health issue, often linked with cardiovascular complications.
- Atrial fibrillation (AF), the most common arrhythmia, affects over 25% of CKD patients aged 70+, increasing stroke and mortality risks.
- CKD patients with AF are frequently undertreated due to limited research and guidelines.
Purpose of the Study:
- To review current epidemiological data on AF, stroke, and bleeding in CKD patients.
- To analyze available oral anticoagulation therapies, including novel agents, in relation to CKD stages.
- To discuss stroke risk stratification for oral anticoagulation in CKD.
Main Methods:
- Literature review of recent data on AF, stroke, and bleeding in CKD.
- Analysis of oral anticoagulation therapies (dabigatran, rivaroxaban, apixaban) based on CKD stage.
- Discussion of stroke risk stratification algorithms for CKD patients.
Main Results:
- AF prevalence is high in CKD patients, especially those on hemodialysis (up to 27%).
- Stroke in CKD patients with AF carries a high mortality rate (55-74% within two years).
- Data on optimal anticoagulation for CKD patients with AF is limited, leading to undertreatment.
Conclusions:
- CKD and AF represent a significant clinical challenge with high risks of thromboembolism and bleeding.
- Further research and clear guidelines are needed for effective anticoagulation management in CKD patients with AF.
- Individualized risk stratification is crucial for optimizing oral anticoagulation therapy in this population.
Abstract:
Due to several unfavorable epidemiological changes, chronic kidney disease (CKD) and treatment of its associated cardiovascular morbidity have become a worldwide problem. Thus, atrial fibrillation (AF) is the most common arrhythmia and frequently associated with renal impairment: prevalence for AF is up to 27% in long-term hemodialysis patients and in general more than 25% in all CKD patients 70 years and older. Thromboembolism and stroke are the major complications of AF. Two-year death rates for CKD patients after stroke range between 55% and 74%. Although treatment of AF in the general population is well defined, patients with CKD and AF are often undertreated due to lack of studies and guidelines. In this review recent data concerning incidence and prevalence of AF, stroke, and major bleedings in CKD patients are presented. Particular attention is paid to the available data about the different types of oral anticoagulation therapy with regard to CKD stage, including the new oral anticoagulant drugs dabigatran, rivaroxaban, and apixaban. Stratification algorithms for stroke risk in general, and individualized risk stratification for oral anticoagulation in CKD patients are discussed in detail.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:29Venous Thrombosis III: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care